Identification and Prioritization of Material Issues
Materiality in CSR activities guides our CSR-based management. Astellas has identified material issues to be addressed based on the issues regarded as prerequisites of its business activities. These include global issues related to medical care and health and other broader social issues.
Making reference to expectations and requests from a broad range of stakeholders, we classified and prioritized the material issues into three categories by evaluating their societal significance and relevance to our business (CSR Materiality Matrix.) In order to tackle these material issues, we are executing a concrete action plan.
Updating of the CSR Materiality Matrix
In the year ended in March 2018, we reviewed the CSR Materiality Matrix in full in order to respond to the changing needs of society. In conducting the review, we spoke with diverse stakeholders (investors, patient groups, doctors, employees, consultants, and academics) in Japan and overseas; examined their feedbacks from a variety of perspectives; deliberated on and approved matters at the CSR Committee, Executive Committee (EC) and Board of Directors; and decided to update the CSR Materiality Matrix.
In this update, we have newly added “tax compliance” and “environmental impacts of pharmaceuticals” in order to respond to the needs of society. Moreover, based on their growing importance, we have moved “customer satisfaction” and “protection of personal and confidential information” to the upper-right quadrant. We have also renamed or combined material issues in order to properly express each material issue.
Materiality Determination Process
Astellas' material issues are identified with reference to various principles and guidelines (such as ISO 26000, the UN Global Compact's ten principles and the SASB* Materiality Map), communications with stakeholders, and evaluation items for Socially Responsible Investment (SRI) indices, etc.
A U.S. non-profit organization exploring industry-specific standards for corporate sustainability disclosure. SASB has prepared industry-specific materiality maps by evaluating the materiality of sustainability topics.
We will prioritize Astellas' material issues from the dual perspectives of societal significance and relevance to our business.
● Dialogue with Stakeholders
● Deliberating on and approving matters at the CSR Committee, EC and Board of Directors
Astellas’ material issues will be reviewed and verified. They will be modified depending on the attainment level of initiatives implemented and/or any changes in the needs of society. In conducting last review, we spoke with stakeholders in Japan and overseas, examined the review, and decided to update the CSR Materiality Matrix after deliberating on and approving matters at the CSR Committee, EC and Board of Directors.
CSR Materiality Matrix
Definitions of material issues
|Development of innovative products and medical solutions||Creating innovative medicines and medical solutions sustainably in therapeutic areas with a high level of unmet medical needs.|
|Responsible R&D||Ensuring the ethical consideration throughout the entire R&D process, and conducting R&D in compliance with global and/or local guidelines, including ethical considerations in animal testing and clinical trials.|
|Responsible marketing and ethical advertising||In compliance with laws and guidelines in each country, ensuring equitable & appropriate marketing and advertising activities, raising customers' awareness about their diseases and treatments to contribute toward improving health.|
|Product pricing||Striking a sustainable balance between fostering innovation and ensuring access to such innovation by setting prices reflecting the benefits of our products.|
|Proper use of products||Enhancing the proper use of our products by Healthcare professionals and patients to ensure patient safety and the efficacy of our products. Considering convenient package design for customers, including those who with disabilities.|
|Product quality assurance and product safety||Ensuring our products are manufactured with appropriate quality assurance standards, and establishing a functional and robust pharmacovigilance system.|
|Anti-counterfeit||Preventing counterfeit drug problems and its improper distribution.|
|Diversity and Inclusion||Ensuring equal opportunity and fair employment regardless of characteristics, including race, nationality, gender, sexual orientation, age or disability.|
|Compliance and ethical business practices||Acting with integrity and making ethical decisions in all aspects of our business, and going beyond compliance with applicable laws, regulations and industry codes. Promoting such behavior through our global compliance structure, the development, implementation, and continuous enhancement of necessary policies and processes, and focusing our activities on Anti-bribery / Anti-corruption compliance, avoiding conflicts of interest, encouraging a "speak-up" culture, and demonstrating our commitment to integrity, ethics and compliance.|
|Access to Health||Developing and delivering necessary healthcare to people around the world by accelerating social benefit-driven research and development, enhancing availability, strengthening healthcare system, and improving health literacy.|
|Protection of personal and confidential information||Appropriately handling confidential information or our stakeholders' personal information, including data obtained in clinical trials, by complying with applicable laws, regulations, and Company policies and procedures.|
|Health, safety and welfare of employees||Ensuring the mental and physical health of employees, and ensuring a safe workplace. Enriching the welfare of employees and their family.|
|Customer satisfaction||Meeting the needs and expectations of customers, such as patients and healthcare professionals, which includes ensuring effective infrastructure and practice to appropriately respond to customers' complaints, inquiries and consultations.|
|Board independence and effectiveness||Ensuring the independence of outside directors based on the "Independence standards for outside directors" established by Astellas and the Tokyo Stock Exchange, Inc. Improving board functionality by analyzing and evaluating its effectiveness.|
|Talent development||Providing career development opportunities that respect the ownership, talent and aptitude of employees.|
|Recruitment and retention of employees||Recruiting and retaining talented people.|
|Fair appraisal and competitive reward||Recognizing the contributions of, and appraising and treating employees in a fair manner according to their role and achievement.|
|CSR procurement||Selecting suppliers in compliance with selection criteria, including CSR* perspectives, such as compliance with laws and respecting human rights. Coaching less-compliant suppliers and supporting their capacity building for improvement through procurement activity.
|Continuous stable supply||Ensuring a continuous stable supply of products.|
|Stakeholder engagement||Having mutual dialogues with multiple stakeholders, including patients and shareholders, to understand their expectations and demands from society, to reflect their opinion of Astellas' business activities and decision-making process.|
|Transparency of corporate activities||Enhancing the transparency of our corporate activities by disclosing information to all stakeholders in a timely, proper, and fair manner regardless of laws and regulations.
・Data and information acquired in research and development activities
・Risk management system and material risks with mitigation plans
|Tax compliance||Complying with the local tax laws and regulations in each country where we operate, and seek to pay the right amount of tax in the right place at the right time.|
|Human rights in labor||Respecting the human rights of employees and business partners, including the elimination of discrimination, the freedom of association and the protection of the rights to organize, and the exclusion of child labor and forced labor.|
|Reduction of environmental burden||Mitigating the environmental burdens caused by business operations to the minimum level, including measures for preventing atmospheric pollution, recycling resources, and management of chemical substances.|
|Environmental impacts of pharmaceuticals||Identifying and managing the environmental impact of our products through their life-cycles from manufacturing to disposal. There is a possibility that the ecological system may be affected by pharmaceuticals discharging into the environment as wastewater from production facilities, active ingredients after being excreted, or improper disposal of leftover drugs.|
|Patient assistance and advocacy||Supporting patient organizations for charitable purposes and conducting advocacy activities*, including funding for patient organization activities, sharing knowledge and information such as holding peer support training sessions, promoting disease awareness through disease awareness events, defending patients' rights, and representing the patient's voice.
|Advancement of medical science||Supporting medical and scientific research which contributes to the advancement of medical sciences.|
|Water management||Using water resources efficiently by reducing volume of withdrawal, reusing, and recycling.|
|Climate change and energy||Reducing greenhouse gas emissions associated with business operations by efficient use of energy.|
|Biodiversity||Mitigating negative impacts on biodiversity and promoting the sustainable use of benefits from biodiversity.|
|Philanthropic community support||Supporting the communities in which we operate. For example, social contribution, such as Disaster Relief, support for employees’ volunteering, and nurturing the next generation.|